Analyses of ABO blood groups with susceptibility and symptomatic variations of COVID-19 infection, a questionnaire-based survey.


Journal

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
ISSN: 1600-0463
Titre abrégé: APMIS
Pays: Denmark
ID NLM: 8803400

Informations de publication

Date de publication:
Oct 2021
Historique:
pubmed: 4 8 2021
medline: 18 9 2021
entrez: 3 8 2021
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) is a novel respiratory disease that has led to a global pandemic and created a havoc. The COVID-19 disease severity varies among individuals, depending on fluctuating symptoms. Many infectious diseases such as hepatitis B and dengue hemorrhagic fever have been associated with ABO blood groups. The aim of this study was to explore whether ABO blood groups might serve as a risk or a protective factor for COVID-19 infection. Moreover, the symptomatic variations of COVID-19 infection among the individuals with different blood groups were also analyzed. An online questionnaire-based survey was conducted in which 305 partakers were included, who had successfully recovered from coronavirus infection. The ABO blood groups of 1294 healthy individuals were also taken as a control. The results of the current study demonstrated that antibody A containing blood groups (blood group B, p-value: 0.049 and blood group O, p-value: 0.289) had a protective role against COVID-19 infection. The comparison of symptomatic variations among COVID-19-infected subjects showed that blood group O subjects had lower chances of experiencing severe symptoms relating to respiratory distress, while subjects with AB blood group were more prone to develop symptoms, but the differences in both groups were found to be statistically non-significant. In conclusion, subjects who do not have anti-A antibodies in their serum (i.e., subjects with group A and AB) are more likely to be infected with COVID-19. The current data showed that there was no significant association of signs and symptoms variations of COVID-19 infection among individuals with different blood groups.

Identifiants

pubmed: 34342074
doi: 10.1111/apm.13169
pmc: PMC8444696
doi:

Substances chimiques

ABO Blood-Group System 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

579-586

Informations de copyright

© 2021 Scandinavian Societies for Medical Microbiology and Pathology.

Références

Br J Haematol. 2020 Jul;190(2):e93-e94
pubmed: 32453863
J Matern Fetal Neonatal Med. 2021 Apr;34(8):1255-1259
pubmed: 31204532
Iran J Public Health. 2014 Jul;43(7):981-9
pubmed: 25909065
Sci Rep. 2018 Dec 4;8(1):17604
pubmed: 30514875
New Microbes New Infect. 2020 Apr 14;35:100681
pubmed: 32322403
Virusdisease. 2018 Mar;29(1):103-105
pubmed: 29607366
J Med Invest. 2008 Aug;55(3-4):174-82
pubmed: 18797129
JAMA. 2005 Mar 23;293(12):1450-1
pubmed: 15784866
Clin Chim Acta. 2020 Oct;509:220-223
pubmed: 32562665
Prz Gastroenterol. 2017;12(3):175-180
pubmed: 29123577
Bull N Y Acad Med. 1973 Feb;49(2):100-11
pubmed: 4567269
Glycobiology. 2008 Dec;18(12):1085-93
pubmed: 18818423
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
FEMS Microbiol Immunol. 1989 Jun;1(6-7):321-30
pubmed: 2698728
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
mSphere. 2016 Mar 30;1(2):
pubmed: 27303720
Acta Trop. 2012 Sep;123(3):164-9
pubmed: 22569530
APMIS. 2021 Oct;129(10):579-586
pubmed: 34342074
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Zhonghua Yi Xue Za Zhi. 2020 Feb 07;100(0):E001
pubmed: 32033513
Clin Microbiol Rev. 2015 Jul;28(3):801-70
pubmed: 26085552
Transfus Med Rev. 2012 Apr;26(2):103-18
pubmed: 21945157
Nat Commun. 2020 Nov 13;11(1):5761
pubmed: 33188185
Transfus Med Rev. 2005 Jan;19(1):32-44
pubmed: 15830326
Infect Genet Evol. 2020 Jul;81:104245
pubmed: 32092482
Mol Biol Rep. 2013 Mar;40(3):2253-61
pubmed: 23184045
Transfus Med Rev. 2000 Oct;14(4):291-301
pubmed: 11055074
PLoS Genet. 2008 May 09;4(5):e1000072
pubmed: 18464913
Epidemiol Infect. 2010 Aug;138(8):1096-9
pubmed: 20003613
Cochrane Database Syst Rev. 2020 Jul 7;7:CD013665
pubmed: 32633856
Wiley Interdiscip Rev Syst Biol Med. 2016 Nov;8(6):517-535
pubmed: 27599872
Infect Genet Evol. 2020 Oct;84:104485
pubmed: 32739464
Glycoconj J. 2000 Jul-Sep;17(7-9):501-30
pubmed: 11421345
J Viral Hepat. 2018 Apr;25(4):401-411
pubmed: 29193618
Trends Microbiol. 2016 Jun;24(6):490-502
pubmed: 27012512
Drugs Ther Perspect. 2020;36(5):213-214
pubmed: 32218652
J Thromb Haemost. 2009 Feb;7(2):263-9
pubmed: 19036074
J Med Virol. 2020 Apr;92(4):418-423
pubmed: 31967327
Eur J Emerg Med. 2015 Oct;22(5):316-20
pubmed: 26035278
Cancer Res. 2010 Feb 1;70(3):1015-23
pubmed: 20103627

Auteurs

Asma Komal (A)

Department of Zoology, The Women University Multan, Multan, Pakistan.

Mamoona Noreen (M)

Department of Zoology, The Women University Multan, Multan, Pakistan.

Junaid Akhtar (J)

Department of Microbiology, University of Health Sciences, Lahore, Pakistan.
Department of Allied Health Sciences, Faculty of Medical & Health Sciences, University of Sargodha, Pakistan.

Muhammad Imran (M)

Department of Microbiology, University of Health Sciences, Lahore, Pakistan.

Muhsin Jamal (M)

Department of Microbiology, Abdul Wali Khan University, Mardan, Pakistan.

Muhammad Atif (M)

Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Kingdom of Saudi Arabia.

Juma Khan (J)

Molecular Laboratory, Sheikh Khalifa Bin Zayyed Hospital, Quetta, Pakistan.

Muhammad Roman (M)

Department of Microbiology, University of Health Sciences, Lahore, Pakistan.

Faiz Ul Haq (F)

Department of Microbiology, University of Health Sciences, Lahore, Pakistan.

Usman Aftab (U)

Department of Pharmacology, University of Health Sciences, Lahore, Pakistan.

Abdul Ghaffar (A)

Department of Pharmacology, University of Health Sciences, Lahore, Pakistan.

Yasir Waheed (Y)

Foundation University Medical College, Foundation University Islamabad, DHA-I, Islamabad, Pakistan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH